Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Medical Physics ; 46 (2019), 12. - S. 5861-5866. - ISSN 0094-2405
- Keyword
-
Medizinische Physik
Nuklearmedizin
- Event
-
Veröffentlichung
- (where)
-
Ulm
- (who)
-
Universität Ulm
- (when)
-
2019
- Creator
- DOI
-
10.18725/OPARU-44309
- URN
-
urn:nbn:de:bsz:289-oparu-44385-4
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rinscheid, Andreas
- Kletting, Peter
- Eiber, Matthias
- Beer, Ambros J.
- Glatting, Gerhard
- Universität Ulm
Time of origin
- 2019
Other Objects (12)
![Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry](/assets/placeholder/searchResultMediaUnknown.png)
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Structural modifications of PSMA ligands to optimize their pharmacokinetics
Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
68Ga-PSMA-11-PET basierte Hybridbildgebung in der Diagnostik des Prostatakarzinomrezidivs nach radikaler Prostatektomie
A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT
Radikale Prostatektomie in Kombination mit der PSMA-Radioguided Surgery bei Patienten mit lymphogen metastasiertem Prostatakarzinom
Application of PSMA-ligands in the uro-oncological theranostics framework : Novel methods to image and treat prostate cancer
Development and Evaluation of Therapeutic PSMA-Binding Radiopharmaceuticals with Optimized Pharmacokinetics
Development of Radiohybrid PSMA Ligands for the Endoradiotherapy of Prostate Cancer
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Structural modifications of PSMA ligands to optimize their pharmacokinetics
Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
68Ga-PSMA-11-PET basierte Hybridbildgebung in der Diagnostik des Prostatakarzinomrezidivs nach radikaler Prostatektomie
A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT
Radikale Prostatektomie in Kombination mit der PSMA-Radioguided Surgery bei Patienten mit lymphogen metastasiertem Prostatakarzinom
Application of PSMA-ligands in the uro-oncological theranostics framework : Novel methods to image and treat prostate cancer
Development and Evaluation of Therapeutic PSMA-Binding Radiopharmaceuticals with Optimized Pharmacokinetics
Development of Radiohybrid PSMA Ligands for the Endoradiotherapy of Prostate Cancer
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Structural modifications of PSMA ligands to optimize their pharmacokinetics
Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms
Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer
68Ga-PSMA-11-PET basierte Hybridbildgebung in der Diagnostik des Prostatakarzinomrezidivs nach radikaler Prostatektomie
A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT
Radikale Prostatektomie in Kombination mit der PSMA-Radioguided Surgery bei Patienten mit lymphogen metastasiertem Prostatakarzinom
Application of PSMA-ligands in the uro-oncological theranostics framework : Novel methods to image and treat prostate cancer
Development and Evaluation of Therapeutic PSMA-Binding Radiopharmaceuticals with Optimized Pharmacokinetics